Affinity DataKi: 17nMAssay Description:Inhibition of N-terminal His6-tagged KAT8 catalytic domain (125 to 458 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as...More data for this Ligand-Target Pair
TargetNAD-dependent protein deacetylase sirtuin-2(Homo sapiens (Human))
University Of Bayreuth
Curated by ChEMBL
University Of Bayreuth
Curated by ChEMBL
Affinity DataKi: 2.18E+3nMAssay Description:Uncompetitive inhibition of human N-terminal His6-SUMO-tagged SIRT2 catalytic domain (43 to 356 residues) deacetylase activity expressed in Escherich...More data for this Ligand-Target Pair
TargetNAD-dependent protein deacetylase sirtuin-2(Homo sapiens (Human))
University Of Bayreuth
Curated by ChEMBL
University Of Bayreuth
Curated by ChEMBL
Affinity DataKi: 2.22E+3nMAssay Description:Uncompetitive inhibition of human N-terminal His6-SUMO-tagged SIRT2 catalytic domain (43 to 356 residues) deacetylase activity expressed in Escherich...More data for this Ligand-Target Pair
Affinity DataKi: 2.60E+3nMAssay Description:Inhibition of N-terminal His6-tagged KAT8 catalytic domain (125 to 458 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetHistone deacetylase(Plasmodium falciparum (isolate 3D7))
Dipartimento Di Chimica E Tecnologie Del Farmaco "Sapienza" Universit£
Curated by ChEMBL
Dipartimento Di Chimica E Tecnologie Del Farmaco "Sapienza" Universit£
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibition of HDAC1 in Plasmodium falciparum 3D7 nuclear extract using Ac-RGK(Ac)-AMC fluorogenic peptide as substrate preincubated for 1 hr followed...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair